Success in Phase 2 Study
In a dynamic arena where companies vie to address the challenging landscape of liver disorders, Inventiva (NASDAQ:IVA) recently soared to a significant milestone. The unveiling of results from a Phase 2 study on the drug lanifibranor shed light on a remarkable achievement: the drug met its primary efficacy endpoint in treating patients grappling with MASH/NASH and type 2 diabetes.
Product Efficacy
Lanifibranor, when paired with empagliflozin, showcased promising results in patients struggling with metabolic dysfunction-associated steatohepatitis, colloquially known as MASH, or scientifically referred to as NASH, combined with type 2 diabetes.
Industry Response
Reactions reverberated across the pharmaceutical sphere as Inventiva unveiled the Phase 2 study’s outcomes. The data revealed an absolute reduction in HbA1c levels, ranging from 1.14% to 1.59% among patients treated with lanifibranor or in conjunction with empagliflozin over a 24-week period. This stark contrasted with an increase of 0.26% observed in the placebo cohort.
Competitive Landscape
Noteworthy advancements have marked the NASH/MASH domain, with Madrigal (MDGL) making waves by securing FDA approval for Rezdiffra, the first-ever treatment for NASH. Amidst this backdrop, a multitude of other entities, including Lilly (LLY), Novo Nordisk (NVO), GSK (GSK), Viking Therapeutics (VKTX), and many more, have intensified their efforts, striving to introduce innovative therapies targeting NASH/MASH.